Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
The Management of Psoriatic Arthritis: A Review
WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…
Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
Sonelokimab Promising for Patients with PsA
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
ACR on Air: A Deep Dive into Psoriatic Arthritis
Hosted by Jonathan S. Hausmann, MD, a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center, and an instructor in medicine at Harvard Medical School, ACR on Air debuted in 2019. In this episode, ACR Master (2016) Philip J. Mease, MD, joins Dr. Hausmann for a deep dive into psoriatic…
New Guidance Proposed for Ultrasound in Psoriatic & Rheumatoid Arthritis
The ACR places a high priority on developing relevant, practical guidance for the rheumatology community. A current ACR project on musculoskeletal ultrasound (MSUS) will be discussed in the ACR Convergence 2024 session, Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis, on Saturday, Nov. 16. In the session, Veena K. Ranganath,…
Sex Matters in PsA
In patients with psoriatic arthritis (PsA), their sex matters. In the session Sex Differences in Psoriatic Arthritis, Laura Coates, MD, PhD, of the University of Oxford, and Lihi Eder, MD, PhD, of the University of Toronto, will discuss sex-related differences in clinical features, disease course, treatment response and pain perception in patients with PsA. The…
Research in Psoriatic Arthritis Most Likely to Make a Difference to Clinical Care
What research on psoriatic arthritis to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts to be presented…
Psoriatic Arthritis, a Management Review
As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, will present a session reviewing the management of psoriatic arthritis. Dr. Orbai earned her medical degree from the Iuliu…
New Indications Possible for Bimekizumab-bkzx
The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 16
- Next Page »